![Brian D. Morgan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Brian D. Morgan
Direktor/Vorstandsmitglied bei Scottish Biomedical
Aktive Positionen von Brian D. Morgan
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Scottish Biomedical
![]() Scottish Biomedical Miscellaneous Commercial ServicesCommercial Services Scottish Biomedical is a British company that specializes in biological research. The private company is based in Glasgow, UK. | Direktor/Vorstandsmitglied | - | - |
The Royal Society of Chemistry
![]() The Royal Society of Chemistry Miscellaneous Commercial ServicesCommercial Services The Royal Society of Chemistry is an organization that supports the chemical sciences community in making the world a better place. The Royal Society of Chemistry is based in London, UK, and has subsidiaries in the United Kingdom. The British company offers various opportunities in education, inclusion, and chemistry's ability to tackle challenges. The organization aims to advance excellence, connect chemical scientists, and shape the future of the chemical sciences for the benefit of humanity. The private company has a publishing portfolio that contains over one million articles, chapters, and records from across the chemical sciences and related fields. The company also provides solutions to help businesses engage with their audience of chemical scientists. | Corporate Officer/Principal | - | - |
Institute of Biology | Corporate Officer/Principal | - | - |
Karriereverlauf von Brian D. Morgan
Ehemalige bekannte Positionen von Brian D. Morgan
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ProtAffin Biotechnologie AG
![]() ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Direktor/Vorstandsmitglied | - | 17.02.2014 |
4SC AG | Direktor/Vorstandsmitglied | 05.06.2008 | 05.06.2008 |
GSK PLC | Corporate Officer/Principal | - | - |
Statistik
International
Vereinigtes Königreich | 5 |
Österreich | 2 |
Deutschland | 2 |
Operativ
Director/Board Member | 3 |
Corporate Officer/Principal | 3 |
Sektoral
Health Technology | 4 |
Commercial Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
GSK PLC | Health Technology |
4SC AG | Health Technology |
Private Unternehmen | 4 |
---|---|
ProtAffin Biotechnologie AG
![]() ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Health Technology |
Scottish Biomedical
![]() Scottish Biomedical Miscellaneous Commercial ServicesCommercial Services Scottish Biomedical is a British company that specializes in biological research. The private company is based in Glasgow, UK. | Commercial Services |
The Royal Society of Chemistry
![]() The Royal Society of Chemistry Miscellaneous Commercial ServicesCommercial Services The Royal Society of Chemistry is an organization that supports the chemical sciences community in making the world a better place. The Royal Society of Chemistry is based in London, UK, and has subsidiaries in the United Kingdom. The British company offers various opportunities in education, inclusion, and chemistry's ability to tackle challenges. The organization aims to advance excellence, connect chemical scientists, and shape the future of the chemical sciences for the benefit of humanity. The private company has a publishing portfolio that contains over one million articles, chapters, and records from across the chemical sciences and related fields. The company also provides solutions to help businesses engage with their audience of chemical scientists. | Commercial Services |
Institute of Biology |
- Börse
- Insiders
- Brian D. Morgan
- Erfahrung